Welcome to our dedicated page for Envoy Medical SEC filings (Ticker: COCH), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Envoy Medical, Inc. filings document a hearing-health company with Class A common stock and redeemable warrants listed on Nasdaq. Its regulatory record covers operating results, financial-condition updates, registration statements for securities offerings, warrant and pre-funded warrant structures, and disclosures related to its status as an emerging growth company.
Company filings also include proxy materials for director elections, auditor ratification, executive compensation, equity incentive and employee stock purchase plan amendments, and Nasdaq share-issuance approvals. Form 8-K disclosures address material agreements, auditor changes, compensatory arrangements, Nasdaq listing compliance, and risk-related matters such as going-concern language in audit reports.
Kantor Susan reported open-market purchase transactions in a Form 4 filing for COCH. The filing lists transactions totaling 249,990 shares at a weighted average price of $0.40 per share. Following the reported transactions, holdings were 57,690 shares.
BRYNELSEN CHARLES reported open-market purchase transactions in a Form 4 filing for COCH. The filing lists transactions totaling 2,600,000 shares at a weighted average price of $0.40 per share. Following the reported transactions, holdings were 600,000 shares.
Lucas Brent T. reported open-market purchase transactions in a Form 4 filing for COCH. The filing lists transactions totaling 162,500 shares at a weighted average price of $0.40 per share. Following the reported transactions, holdings were 37,500 shares.
TAYLOR GLEN A reported open-market purchase transactions in a Form 4 filing for COCH. The filing lists transactions totaling 48,750,000 shares at a weighted average price of $0.40 per share. Following the reported transactions, holdings were 11,250,000 shares.
Envoy Medical stockholder Glen A. Taylor filed an amended Schedule 13D to update his ownership after a February 2026 investment. He purchased 18,750,000 shares of Class A Common Stock together with Series A-1 Warrants for 11,250,000 shares and Series A-2 Warrants for 18,750,000 shares at a combined price of $0.40 per share and accompanying warrants, for an aggregate $7,500,000 funded with personal funds.
The common warrants have a $0.40 exercise price and become exercisable after stockholder approval of the warrant share issuance, with Series A-1 Warrants expiring up to 24 months after that approval (or earlier upon Milestone 1) and Series A-2 Warrants up to 60 months (or earlier upon Milestone 2). As of February 12, 2025, he is treated as beneficially owning 68,909,614 shares of Class A Common Stock, or 84.8% of the class, based on 76,881,110 shares outstanding immediately following the company’s offering, including the warrant shares. On the same date, he directly holds 29,040,049 outstanding shares, or 37.7% of those outstanding shares.
Envoy Medical, Inc. completed an upsized public offering that raised approximately $30.0 million in gross proceeds by selling an aggregate of 75,000,000 shares of Class A common stock (or pre-funded warrants in lieu) plus milestone-linked Series A-1 and Series A-2 warrants to purchase up to 120,000,000 additional shares.
The warrants carry a $0.40 exercise price and become exercisable after stockholder approval, with earlier expirations tied to FDA milestones for the company’s Acclaim cochlear implant. If fully exercised for cash, the warrants could bring in about $48.0 million more. Envoy plans to use the net proceeds for working capital and to fund its pivotal FDA clinical study, and it expects the financing to extend its cash runway into the second half of 2027.
Envoy Medical is registering up to 150,803,850 shares of Class A common stock underlying pre-funded, Series A-1, Series A-2 and placement agent warrants, alongside 47,946,150 shares of common stock and 27,053,850 pre-funded warrants sold in a best-efforts public offering at $0.40 per share and accompanying warrants. The deal implies a maximum gross raise of about $30.0 million and estimated net proceeds of roughly $27.8 million before any warrant exercises. There is no minimum offering amount, and H.C. Wainwright is acting as exclusive placement agent.
Common stock outstanding would rise from 28,934,960 to 103,934,960 shares if all pre-funded warrants are exercised and none of the new common or placement agent warrants are exercised. Company insiders are committing about $8.4 million of the raise. Envoy remains a loss-making, emerging growth medical device company, advancing its fully implanted Acclaim cochlear implant through a pivotal trial while facing Nasdaq listing compliance pressures and substantial ongoing capital needs.
Envoy Medical, Inc. is registering up to 150,803,850 shares of Class A common stock issuable from pre-funded, Series A-1, Series A-2 and placement agent warrants, alongside 47,946,150 new shares in a primary offering of stock and warrants at $0.40 per share and accompanying warrants.
The company expects gross proceeds of about $30.0 million and estimated net proceeds of roughly $27.8 million, with no minimum offering requirement in this reasonable best-efforts deal led by H.C. Wainwright. Company insiders plan to buy about 21.0 million shares plus warrants for approximately $8.4 million. Shares outstanding are expected to rise from 28,934,960 to 103,934,960, assuming all pre-funded warrants are exercised and no additional warrants are exercised.
Envoy is a hearing-health company developing the fully implanted Acclaim cochlear implant, now in the final stage of a pivotal U.S. trial, and has never been profitable. It reported net losses of $17.2 million for the nine months ended September 30, 2025 and carries a going-concern warning. The company also faces Nasdaq compliance pressures related to market value and minimum bid price listing standards.
Envoy Medical, Inc. reported that its Compensation Committee approved new stock option grants for its Chief Executive Officer and Interim Chief Financial Officer under the company’s 2023 Equity Incentive Plan.
On February 5, 2026, CEO Brent Lucas received options to purchase 200,000 shares of Class A common stock, and Interim CFO Robert Potashnick received options for 15,000 shares. Both grants have an exercise price of $0.53 per share, matching the closing price on the Nasdaq Capital Market on the award date. Twenty‑five percent of each grant vests after one year, with the remaining options vesting pro rata over the following 36 months, and each award has a 10‑year term.